Novel Agent Demonstrates Activity in Heavily Pretreated Ovarian Cancer That Progressed on Pegylated Doxorubicin
Links shared publicly online about this topic.
- 104total visits
Novel Agent Demonstrates Activity in Heavily Pretreated Ovarian Cancer That Progressed on Pegylated Doxorubicin
A novel topoisomerase-I inhibitor designated NKTR-102 demonstrated clinically significant activity as a single agent in patients with heavily pretreated ovarian cancer who failed prior PLD.
View full resource at onclive.com
Tags: Cancer, Ovarian Cancer, Women's Health
Most Recently Shared on August 1, 2011 at 2:29 pm By:
Novel Agent Demonstrates Activity in Heavily Pretreated Ovarian Cancer That Progressed on Pegylated Doxorubicin http://t.co/jz7fFD3
Advertisement
